Successful clinical translation of advanced cell therapies requires more than manufacturing capacity. It requires a development strategy that integrates process understanding, analytical characterization, quality, and manufacturability from the earliest stages of development.
At Evotec, we bring development, analytics, quality, and GMP manufacturing together within one integrated CDMO platform. By connecting expertise across disciplines from day one, we ensure knowledge continuity and informed decision-making throughout the program lifecycle. With the speed, flexibility, and partnership of an agile team, we support autologous, allogeneic, and iPSC-derived programs through robust, scalable, and regulatory-aligned processes that simplify complexity and streamline the path from development to clinical manufacturing.
One Team. One Site. No Handovers
Reduced handovers, aligned expertise, and continuous program ownership reduce technology transfer risk and accelerate progression toward clinical manufacturing. Backed by more than a decade of experience in advanced cell therapy development and manufacturing, including iPSC-derived and mesoangioblast-based programs, we help innovators advance complex cell therapy programs with confidence.
Learn More About Our Offering
Designed for GMP. Built for Manufacturing Success
Using a Quality-by-Design (QbD) and risk-based approach, we establish GMP-ready processes from the outset. By embedding manufacturability early, we create scalable and regulatory-aligned processes that support successful clinical translation and future growth.
Contact Our Cell Therapy Team
Our flexible engagement model is tailored to the needs of each program, from focused development and manufacturing services to integrated end-to-end support. Contact us to discuss your cell therapy goals.
